Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
MethylGene logo — Harnessing Innovation to Develop Next-Generation Cancer Ther...

MethylGene

Harnessing Innovation to Develop Next-Generation Cancer Therapies

Founded 1997 Venture round Total: $71.83M Biopharma, Biotechnology

General Information

Company Name MethylGene
Founded Year 1997
Industries Biopharma, Biotechnology
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with MethylGene. To contact MethylGene, visit methylgene.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does MethylGene compare?

A PDF of MethylGene and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting MethylGene soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About MethylGene

MethylGene is a clinical stage biopharmaceutical company dedicated to the development and commercialization of innovative therapeutics primarily targeting cancer. Founded in 1997, it trades on the public market under the symbol TSX:MYG. The company's product portfolio includes MGCD265, an oral, multi-targeted kinase inhibitor currently in various clinical trials for cancer treatment. Another candidate, MGCD290, is a fungal Hos2 inhibitor intended for use with fluconazole for severe fungal infections and has successfully completed Phase I clinical studies. Mocetinostat (MGCD0103), an oral, isoform-selective HDAC inhibitor, has shown promise in numerous Phase II trials for cancer, currently undergoing a Phase II trial for refractory or relapsed follicular lymphoma and licensed to Taiho Pharmaceutical Co. Ltd in select Asian territories. Additionally, a compound from MethylGene's HDAC platform, EVP-0334, aimed at enhancing cognition in neurodegenerative disorders, has completed Phase I trials with EnVivo Pharmaceuticals Inc. The company benefits from a funded collaboration with Otsuka Pharmaceutical Co. Ltd. for ocular disease applications based on its proprietary kinase inhibitor chemistry. MethylGene received a $26.13M Venture Round investment on 21 November 2012 from OrbiMed, Tavistock Group, Baker Brothers Advisors LLC, and Tang Capital Management. With its diverse product pipeline and established partnerships, MethylGene is positioned to make significant contributions to the field of biopharmaceuticals.

Business keywords: biopharmaceutical company, clinical stage, cancer therapeutics, kinase inhibitors, HDAC inhibitors, oncology, pharmaceutical research, clinical trials, drug development, neurodegenerative diseases, publicly traded, Oncology treatments, MethylGene Inc., Taiho Pharmaceutical Co. Ltd.

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $26.13M 4
OrbiMed Tavistock Group
OrbiMed, Tavistock Group +2
21 Nov 2012
Venture Round $34.50M 6
OrbiMed Tavistock Group QVT Financial LP
OrbiMed, Tavistock Group +4
24 Mar 2011
Venture Round Undisclosed -
01 Jan 2005
Venture Round $11.20M -
01 Jan 1999

MethylGene Alternatives & Competitors

View All Alternatives
MethylGene vs
KeifeRx
KeifeRx United States

KeifeRx is a biopharmaceutical company finding disease-modifying treatments for neurodegenerative di...

Series A
7 employees
Biopharma, Biotechnology
MethylGene vs
ORIC Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc. United States

Overcoming Resistance In Cancer

Post-IPO Equity
119 employees
Biopharma, Biotechnology
MethylGene vs
Onconova Therapeutics
Onconova Therapeutics United States

Onconova is focused on discovering and developing novel products for patients with cancer.

Post-IPO Equity
20 employees
Biopharma, Biotechnology
View all alternatives

FAQ About MethylGene

Harnessing Innovation to Develop Next-Generation Cancer Therapies
MethylGene was founded in 1997.
MethylGene operates in Biopharma and Biotechnology. Its work centres on biopharmaceutical company, clinical stage, cancer therapeutics and kinase inhibitors.
MethylGene has completed 4 funding rounds, raising a total of $71.83M. The latest funding stage is Venture round.
Top alternatives and competitors to MethylGene include KeifeRx, ORIC Pharmaceuticals Inc., Onconova Therapeutics, Ambit, Arno Therapeutics Inc (ARNI). These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
MethylGene and KeifeRx are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for MethylGene, https://bouncewatch.com/company/methylgene, updated 11 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes